•Rapid and persisting clinical and laboratory response•Disease flares after therapy withdrawal•Infections as the most common AEs•Up-reglated inflammasome/IL-1 and IFN signitures in active anduntreated patients with down-regulation after therapy initiation. This evidence concerns the gene IL1B and infection.